FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Study to Evaluate Semaglutide and Tirzepatide in Combination with Digital Health Programs for Weight Loss
返回研究图书馆

Study to Evaluate Semaglutide and Tirzepatide in Combination with Digital Health Programs for Weight Loss

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

Study to Evaluate Semaglutide and Tirzepatide in Combination with Digital Health Programs for Weight Loss

A new study set to launch in 2026 will explore how digital health programs, when combined with peptide therapy, can enhance weight loss outcomes. The FLOURISH and THRIVE studies are being conducted by Noom Inc., a leading provider of digital health solutions, and aim to evaluate the real-world effectiveness of their program on metabolic health markers.

Background

Obesity and overweight conditions continue to be major public health challenges globally, with an increasing emphasis on innovative approaches to weight management. One such approach involves combining behavioral change programs with pharmacological interventions like GLP-1 receptor agonists (GLP-1RAs), which include semaglutide and tirzepatide. These peptides have shown promise in clinical trials for their ability to reduce body weight and improve metabolic health markers.

The FLOURISH and THRIVE studies are designed to build on this foundation by examining the synergistic effects of Noom's digital health programs, specifically its Noom Weight platform, with both semaglutide and tirzepatide. By offering a comprehensive approach that integrates behavioral modification techniques with peptide therapy, these studies aim to provide valuable insights into how patients can achieve sustainable weight loss.

Key Details

The research program includes two prospective cohort studies: FLOURISH and THRIVE. These studies are currently not recruiting participants but will evaluate the effectiveness of Noom's digital health programs combined with various dosages of semaglutide and tirzepatide on weight, cardiometabolic biomarkers, and physiological health indicators.

  • FLOURISH Study: This six-arm study compares an education-only control group with several intervention groups receiving either standard-dose or microdose compounded semaglutide and standard-dose or microdose tirzepatide. The Noom Weight platform will be used to deliver behavioral interventions alongside the medication.
  • THRIVE Study: Although details are not fully disclosed, this study aims to extend the evaluation of these combined therapies over a longer period, assessing long-term sustainability and overall health outcomes.

The primary objective is to determine if integrating digital behavior change programs with GLP-1RAs can lead to better weight loss and improved metabolic profiles compared to standalone interventions. Secondary objectives include evaluating program engagement metrics and adherence rates among participants.

Key Takeaways

  • The FLOURISH and THRIVE studies aim to investigate the effectiveness of combining Noom's digital health programs with semaglutide and tirzepatide for weight management.
  • Both standard-dose and microdose forms of these GLP-1RAs will be evaluated alongside behavioral interventions in a multi-arm design.
  • The research seeks to provide evidence on how integrating pharmacological and behavioral approaches can improve metabolic health outcomes.

What This Means

This study highlights the growing trend towards holistic approaches in weight management, combining digital tools with peptide therapy. As researchers continue to explore the full potential of GLP-1RAs like semaglutide and tirzepatide, these findings could significantly impact clinical guidelines for obesity treatment. For the peptide community, this research underscores the importance of considering lifestyle modifications alongside pharmacological interventions to achieve optimal patient outcomes.

---

Source: ClinicalTrials.gov — Published 2026-05-15

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。